drugset / Trial / NCT01493180

Exploratory Study of OPC-12759 Ophthalmic Suspension

NCT01493180

Phase 2 Completed 102 enrolled Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of OPC-12759 ophthalmic suspension for patients with keratoconjunctival epithelial disorder compared with sodium hyaluronate. Also, safety of OPC-12759 is to be assessed.

Timeline

Start
2011-12
Primary completion
2012-11
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rebamipide Small molecule 2 %
Comparator Sodium Hyaluronate Other / unclassified 0.1 %

Indications